Cytosorbents (CTSO) to Release Quarterly Earnings on Thursday

Cytosorbents (NASDAQ:CTSO) will be issuing its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect Cytosorbents to post earnings of ($0.06) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Tuesday, August 13th. The medical research company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.01. Cytosorbents had a negative net margin of 68.70% and a negative return on equity of 131.84%. The company had revenue of $9.89 million for the quarter, compared to the consensus estimate of $9.73 million. During the same period in the prior year, the firm posted ($0.14) EPS. On average, analysts expect Cytosorbents to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytosorbents Trading Down 13.0 %

NASDAQ CTSO opened at $0.87 on Tuesday. The company has a 50-day moving average price of $1.15 and a 200-day moving average price of $1.01. The company has a quick ratio of 1.71, a current ratio of 2.12 and a debt-to-equity ratio of 0.82. Cytosorbents has a 52 week low of $0.70 and a 52 week high of $2.15.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on CTSO shares. EF Hutton Acquisition Co. I raised Cytosorbents to a “strong-buy” rating in a research note on Monday, July 29th. HC Wainwright reaffirmed a “neutral” rating and issued a $1.00 price objective on shares of Cytosorbents in a research report on Wednesday, August 14th. Finally, StockNews.com assumed coverage on Cytosorbents in a research report on Saturday. They set a “hold” rating on the stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.